08:00 , Mar 13, 2000 |  BioCentury  |  Emerging Company Profile

Rosetta Inpharmatics: Decoding genomics

The next 10 years will see an exponential increase in the amount of expression data available to analyze gene function. While it is now straightforward to generate the data, what is more problematic is the...
08:00 , Mar 1, 1999 |  BC Week In Review  |  Company News

Acacia Biosciences Inc., Rosetta deal

Rosetta completed its acquisition of Acacia in a stock transaction (see BioCentury, Feb. 8). Acacia Biosciences Inc. , Richmond, Calif.   Rosetta Inpharmatics Inc. , Kirkland, Wash.   Business: Drug discovery  ...
08:00 , Feb 8, 1999 |  BC Week In Review  |  Company News

Acacia Biosciences Inc., Rosetta deal

Rosetta will acquire Acacia in a stock transaction. Rosetta plans to integrate Acacia's Genome Reporter Matrix technology, which profiles the impact of a drug candidate on multiple gene pathways, into its system of informatics tools,...
08:00 , Nov 9, 1998 |  BC Week In Review  |  Company News

Acacia BioSciences Inc. other research news

Acacia received a $1 million grant from the Office of Biological and Environmental Research of the DOE to measure response of yeast to a panel of environmentally important compounds and ionizing radiation, to determine changes...
08:00 , Nov 9, 1998 |  BioCentury  |  Tools & Techniques

Profiling therapeutic precision

The ideal drug would exhibit pure action at a single site. Such pinpoint precision would work as if a single gene were switched off. Rosetta Inpharmatics is pursuing technology aimed at helping drug designers determine...
08:00 , Oct 26, 1998 |  BC Week In Review  |  Company News

Acacia Biosciences Inc., Aurora enabling technology news

ABSC withdrew its patent infringement suit against Acacia filed in the U.S. District Court in San Diego. In return, Acacia agreed not to challenge ABSC's fluorescent protein patents. Under the settlement, Acacia will receive non-exclusive...
07:00 , Aug 24, 1998 |  BC Week In Review  |  Company News

Acacia Biosciences Inc., Novartis Crop Protection Inc. deal

Acacia will use its Genome Reporter Matrix technology to provide chemical and biological response profiles on a class of Novartis compounds to help select and optimize lead crop protection candidates. Acacia will receive a payment...
07:00 , Aug 10, 1998 |  BC Week In Review  |  Company News

Acacia Biosciences Inc. other research news

Acacia received three Phase I SBIR grants for further development of its genome technology and drug discovery activities. Two $140,000 grants from the National Institute of General Medical Sciences will fund the demonstration that certain...
07:00 , Jul 20, 1998 |  BC Week In Review  |  Clinical News

Acacia Biosciences Inc., University of California regulatory update

The university received U.S. Patent No. 5,777,888 covering methods for generating and storing data for technologies that measure and interpret gene expression for functional genomics. Acacia has exclusive rights to the patent. Acacia Biosciences Inc.,...
07:00 , Jun 15, 1998 |  BC Week In Review  |  Company News

Acacia Biosciences Inc., DuPont Agricultural Enterprise deal

Acacia will provide chemical and biological profiles on a class of DuPont’s compounds that have potential for use in crop protection using Acacia’s Genome Reporter Matrix to select and optimize lead compounds. Acacia Biosciences Inc....